Solid Biosciences CEO Bo Cumbo discusses recent DMD data for the company's microdystrophin gene therapy, and explains the development and regulatory steps ahead
- Mar 25
- 1 min read
He describes data presented at the 2026 Muscular Dystrophy Association Annual Meeting, which showed biopsy and safety data for 20 patients who have been followed for 90 days and 3 who are out to a year. Plus, explaining the three FDA meetings that are key for the company.
.png){kind=logo}